Business Context and Reporting Period
Company: SeaStar Medical Holding Corp (ICU)
Filing Type: Form 8-K (Current Report)
Report Date: February 21, 2024 (Event Date: February 22, 2024)
Context: The filing reports a significant regulatory milestone regarding the Company's Selective Cytopheretic Device Pediatric.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Regulatory Approval: On February 22, 2024, the U.S. Food and Drug Administration (FDA) granted the Company a Humanitarian Device Exemption (HDE) Approval Order.
- Device: Selective Cytopheretic Device Pediatric.
- Indication: Use in children weighing 10 kilograms or more with acute kidney injury and sepsis, or with a septic condition on continuous kidney replacement therapy in the hospital intensive care unit.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the FDA approval but does not include forward-looking guidance, financial outlook, or specific risk factors within the text of this report.
Unusual Items: The primary event is the receipt of the HDE Approval Order, which is a non-routine regulatory development.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on commercialization plans or limitations of the HDE approval.
- Confirm the specific patient population criteria (weight and condition) for the approved device.
- Review subsequent filings for any financial impact or revenue recognition related to this approval.
- Check the Company's status as an emerging growth company for potential reporting exemptions.